Hantavirus vaccine - Pierre Fabre/Institut Rega

Drug Profile

Hantavirus vaccine - Pierre Fabre/Institut Rega

Latest Information Update: 21 Aug 2007

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Pierre Fabre; Rega Institute for Medical Research
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hantavirus infections

Most Recent Events

  • 19 Oct 2005 No development reported - Preclinical for Hantavirus infections in Belgium (unspecified route)
  • 19 Oct 2005 No development reported - Preclinical for Hantavirus infections in France (unspecified route)
  • 28 Nov 2002 This vaccine is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top